Company: SNSE
Filing Date: 2025-03-27
Form Type: 8-K
Source: 0001193125-25-065634
Chunk: 0

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-03-27
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On March 27, 2025, Sensei Biotherapeutics, Inc. (the “ Company”) issued a press release titled “ Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1Resistant Tumors.” The press release also included information regarding a conference call to discuss the clinical trial results. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company is also updating its corporate presentation on its website, which the Company will reference during the conference call described above. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 and the exhibits attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.